February 24, 2023 02:49 PM EST
Pharma
Coronavirus

Eu­ro­pean reg­u­la­tors rec­om­mend re­jec­tion of Mer­ck’s Covid-19 drug mol­nupi­ravir

Paul Schloesser

Associate Editor

Eu­ro­pean reg­u­la­tors rec­om­mend­ed the EMA re­ject Mer­ck’s Covid an­tivi­ral, say­ing that there’s not enough ev­i­dence it works in pa­tients.

Mer­ck and part­ner Ridge­back Bio­ther­a­peu­tics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump says he'll sign or­der on 'most fa­vored na­tion' drug price plans Mon­day

Lil­ly says fur­ther head-to-head tri­al da­ta back Zep­bound over No­vo’s We­govy

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

A service from the Financial Times